Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
Hookipa Biotech GmbH
Incyte Corporation
Bristol-Myers Squibb
University of Pittsburgh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Compugen Ltd
UNICANCER
The Netherlands Cancer Institute
Bristol-Myers Squibb
Bristol-Myers Squibb
Fate Therapeutics
Five Prime Therapeutics, Inc.
Oncovir, Inc.